Literature DB >> 18159172

[Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease].

So Young Bang1, Dong Soo Han, Chang Soo Eun, Ji Eun Kim, Sang Bong Ahn, Joo Hyun Sohn, Yong Cheol Jeon, Jung Oak Kang.   

Abstract

BACKGROUND/AIMS: Antibiotic resistance of Helicobacter pylori (H. pylori) is a significant clinical problem because it reduces the efficacy of eradication therapy. The aims of this study were to assess the changing patterns of antibiotic resistance of H. pylori in patients with peptic ulcer diseases and to evaluate the eradication rate in antibiotic resistant H. pylori strains.
METHODS: One hundred forty four H. pylori isolates obtained from 466 patients with peptic ulcer disease between June 2001 and December 2005 were examined for antimicrobial resistance. The minimum inhibitory concentration (MIC) of metronidazole was determined by modified broth microdilution method (mBMD) and E test. MICs of clarithromycin and amoxicillin were determined by mBMD, E test, and disc diffusion test. The breakpoints for metronidazole, clarithromycin, and amoxicillin resistance were defined as >8 microg/mL, >1 microg/mL, and > or =1 microg/mL, respectively.
RESULTS: Resistance to metronidazole and clarithromycin was detected in 34.7% and 16.7% of H. pylori isolates, respectively. During the recent 5-year study period, amoxicillin-resistant rate of H. pylori was 11.8%, and multi-drug resistance rate of H. pylori was 16.7%. The eradication rate of clarithromycin containing triple therapies was low (7.8%) in clarithromycin-resistant H. pylori strains.
CONCLUSIONS: The proportions of clarithromycin-resistant H. pylori strains have increased significantly over the last 5-years. There is an increasing tendency for the emergence of strains with multi-drug resistance. The increase in clarithromycin-resistant strains results in a decrease in eradication rate for H. pylori. In areas with high clarithromycin resistance, new alternative first-line treatment combination should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18159172

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  12 in total

1.  Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

2.  Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

Authors:  Hyuk Soon Choi; Hoon Jai Chun; Sang Hoon Park; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon-Tae Jeen; Soon Ho Um; Hong Sik Lee; Chang Duck Kim; Ho Sang Ryu
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

Review 3.  Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.

Authors:  Ariolana A Dos Santos; Adriana A Carvalho
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

4.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.

Authors:  Hassan Seddik; Samir Ahid; Tarek El Adioui; Fatim-Zohra El Hamdi; Mohammed Hassar; Redouane Abouqal; Yahia Cherrah; Ahmed Benkirane
Journal:  Eur J Clin Pharmacol       Date:  2013-05-22       Impact factor: 2.953

5.  Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.

Authors:  Young Woon Chang; Ga Young Shin; Jung-Wook Kim; Jin-Chang Moon; Eun Jee Chang; Chi Hyuk Oh; Jae-Young Jang
Journal:  Dig Dis Sci       Date:  2021-03-23       Impact factor: 3.199

6.  Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.

Authors:  Kang Hyun Choi; Woo Chul Chung; Kang-Moon Lee; Chang Nyol Paik; Eun Jung Kim; Bong Koo Kang; Ju Hyun Oak; Sung Hoon Jung
Journal:  J Korean Med Sci       Date:  2011-05-18       Impact factor: 2.153

7.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

8.  Helicobacter pylori in vegetables and salads: genotyping and antimicrobial resistance properties.

Authors:  Emad Yahaghi; Faham Khamesipour; Fatemeh Mashayekhi; Farhad Safarpoor Dehkordi; Mohammad Hossein Sakhaei; Mojtaba Masoudimanesh; Maryam Khayyat Khameneie
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411

9.  Virulence factors and antibiotic resistance of Helicobacter pylori isolated from raw milk and unpasteurized dairy products in Iran.

Authors:  Soolmaz Mousavi; Farhad Safarpoor Dehkordi; Ebrahim Rahimi
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2014-12-04

10.  Helicobacter pylori in bottled mineral water: genotyping and antimicrobial resistance properties.

Authors:  Reza Ranjbar; Faham Khamesipour; Nematollah Jonaidi-Jafari; Ebrahim Rahimi
Journal:  BMC Microbiol       Date:  2016-03-12       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.